Susan Escudier, MD, FACP, vice president of value-based and quality programs for Texas Oncology, discusses how collaboration between oncologists and primary care physicians (PCPs) can improve patient satisfaction and outcomes.
Both oncologists and primary care physicians need to work together to improve patient outcomes while also maintaining cost-effective strategies, says Susan Escudier, MD, FACP, vice president, value-based care and quality programs for Texas Oncology.
Transcript
What should cancer specialists know about working with primary care?
I think it's very important to realize that we have overlapping goals, but our goals are not identical. The primary care organizations have to take care of all the patient's needs. And I think that is actually quite valuable to us because they can give us assistance helping patients stay on treatment by managing their comorbidities, by managing their other medications. I think that they want to be in the loop, they want to know what's going on, and they want to have some say, at times, in terms of where do we refer the patient to for things like surgeries or imaging. They may have specific value-based care contracts that require them to use certain institutions over others.
What metrics or key performance indicators should be considered to measure the success of a value-based partnership between oncology specialists and primary care physicians?
I think it's really important that we look at patient outcomes. We have to have good patient outcomes because care can't be cost-effective unless it’s effective. We want to make sure that the oncologists are following national guidelines; we want to meet the quality criteria, patient satisfaction, and the cost of care. We have to show that we've got a handle on the cost of care without compromising patient outcomes.
What value-based strategies or interventions can be/or have been implemented to ensure seamless transitions of care between oncology specialists and primary care physicians?
I think it's really all about communication and being responsive. Our practice, for example, has an initiative to get new cancer patients in very quickly so that those patients can get taken care of, and that's going to help with our patient satisfaction scores. I think that we have to be in line with their priorities in terms of the insurance companies and the payers. So, for example, if we're in an ACO [accountable care organization] and we send consultations or imaging outside of the ACO institutions, that may have an unfavorable outcome in terms of the primary care physician meeting their metrics, as well as ours.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More